



Opportunities to Impact Research on Schizophrenia: The Journey Studies

If you or someone you know is living with schizophrenia, the Journey Studies may be of interest. The Journey Studies are currently enrolling people 18 years of age or older who have been diagnosed with schizophrenia and are still experiencing symptoms while on treatment with antipsychotics.

These studies are researching the safety and efficacy of an investigational drug, called valbenazine, on symptoms of schizophrenia. The investigational drug is a once-daily oral medication. Researchers are assessing the effects of the investigational drug in relation to a placebo (a substance without active medication) in the 10-week treatment period of the study, which can last up to 16 weeks.

All participants will:

- Receive close follow-up by a study doctor in addition to their current doctor(s)
- Continue their current schizophrenia treatment
- Receive study-related medical exams and laboratory tests at no cost

Visit JourneyStudiesResearch.com to learn more.

About Clinical Research Studies

Clinical research studies, also called clinical trials, look at an investigational drug or medical device to see if it is safe, how it works in the body, and if it works to treat a specific disease. Clinical research studies are conducted by doctors who are responsible for the study participants' study-related care.

Participation in any clinical research study is completely voluntary, and you may withdraw from the study at any time for any reason. Before participating in a clinical research study, it is important to weigh the potential risks and benefits of participation, as well as possible side effects, which the study team will review with you. To make an informed decision, gather as much information as possible and talk to your healthcare providers about any questions you may have.

S&PAA does not endorse, recommend or favor and makes no claims, promises or guarantees about this clinical study and expressly disclaims liability. S&PAA has received funding from Neurocrine Biosciences, Inc. to distribute these materials.

NBI-98854_ATS3019_ATS3020_S&PAAWebsiteListing_V2_10Oct2023